An overview of vortioxetine.

Abstract

Six clinicians provide an overview of the serotonergic antidepressant vortioxetine, which was recently approved for the treatment of major depressive disorder in adults. They discuss the pharmacologic profile and receptor-mediated effects of vortioxetine in relation to potential outcomes. Additionally, they summarize the clinical trials, which demonstrate vortioxetine's efficacy, and discuss findings related to safety and tolerability that have high relevance to patient compliance.

• Authors: Alan F Schatzberg, Pierre Blier, Larry Culpepper, Rakesh Jain, George I Papakostas, Michael E Thase
• Journal: The Journal of clinical psychiatry (J Clin Psychiatry) Vol. 75 Issue 12 Pg. 1411-8 (Dec 2014) ISSN: 1555-2101 [Electronic] United States
• PMID: 25551236 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
• Copyright: © Copyright 2014 Physicians Postgraduate Press, Inc.

Chemical References

• Antidepressive Agents
• Antipsychotic Agents
• Piperazines
• Receptors, Serotonin
• Serotonin Plasma Membrane Transport Proteins
• Sulfides
• Vortioxetine

Topics

• Animals
• Antidepressive Agents (adverse effects, pharmacology, therapeutic use)
• Antipsychotic Agents (pharmacology)
• Depressive Disorder, Major (drug therapy)
• Dose-Response Relationship, Drug
• Humans
• Numbers Needed To Treat
• Piperazines (adverse effects, pharmacology, therapeutic use)
• Primary Health Care
• Receptors, Serotonin (drug effects)
• Recurrence
• Serotonin Plasma Membrane Transport Proteins (drug effects)
• Sulfides (adverse effects, pharmacology, therapeutic use)
• Vortioxetine